1. Surgical and Survival Outcomes Following Pelvic Exenteration for Locally Advanced Primary Rectal Cancer Results From an International Collaboration
- Author
-
Kelly ME, Glynn R, Aalbers AGJ, Alberda W, Antoniou A, Austin KK, Beets GL, Beynon J, Bosman SJ, Brunner M, Buchler MW, Burger JWA, Campain N, Christensen HK, Codd M, Coscia M, Colquhoun A, Daniels I, Davies RJ, de Wilt JHW, Deutsch C, Dietz D, Eglinton T, Fearnhead N, Frizelle FA, Garcia-Sabrido JL, George M, Gentilini L, Harris DA, Harji D, Herriot AG, Hohenberger W, Jenkins JT, Kanemitsu Y, Karen Kar Loen C, Kim H, Koh CE, Kok N, Kontovounisios C, Kulu Y, Law WL, Laurberg S, Le GN, Lydrup ML, Lynch AC, Martling A, Meijerink J, Merkel S, McDermott FD, McGrath J, Nielsen MB, Nieuwenhuijzen GAP, Nordling MA, Northover JMA, O’Connell PR, Patsouras D, Poggioli G, Radwan RW, Rasheed S, Rasmussen PC, Rutten HJT, Sagar PM, Schizas A, Shida D, Smart N, Solomon MJ, Stocchi L, Tekkis PP, Tsukamoto S, Turner W, Tuynman J, Ulrich A, van Leeuwenhoek A, van Ramshorst GH, Vasquez-Jimenez W, Verhoef C, Versteegen M, Wakeman C, Warrier S, Yip J, Winter DC., Kelly ME, Glynn R, Aalbers AGJ, Alberda W, Antoniou A, Austin KK, Beets GL, Beynon J, Bosman SJ, Brunner M, Buchler MW, Burger JWA, Campain N, Christensen HK, Codd M, Coscia M, Colquhoun A, Daniels I, Davies RJ, de Wilt JHW, Deutsch C, Dietz D, Eglinton T, Fearnhead N, Frizelle FA, Garcia-Sabrido JL, George M, Gentilini L, Harris DA, Harji D, Herriot AG, Hohenberger W, Jenkins JT, Kanemitsu Y, Karen Kar Loen C, Kim H, Koh CE, Kok N, Kontovounisios C, Kulu Y, Law WL, Laurberg S, Le GN, Lydrup ML, Lynch AC, Martling A, Meijerink J, Merkel S, McDermott FD, McGrath J, Nielsen MB, Nieuwenhuijzen GAP, Nordling MA, Northover JMA, O’Connell PR, Patsouras D, Poggioli G, Radwan RW, Rasheed S, Rasmussen PC, Rutten HJT, Sagar PM, Schizas A, Shida D, Smart N, Solomon MJ, Stocchi L, Tekkis PP, Tsukamoto S, Turner W, Tuynman J, Ulrich A, van Leeuwenhoek A, van Ramshorst GH, Vasquez-Jimenez W, Verhoef C, Versteegen M, Wakeman C, Warrier S, Yip J, Winter DC., and Surgery
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Colorectal cancer ,medicine.medical_treatment ,International Cooperation ,Cohort Studies ,03 medical and health sciences ,Young Adult ,Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14] ,0302 clinical medicine ,All institutes and research themes of the Radboud University Medical Center ,international collaboration, locally advanced, rectal cancer, surgical outcomes, survival outcomes ,SDG 3 - Good Health and Well-being ,Clinical endpoint ,Medicine ,Humans ,Survival rate ,Neoadjuvant therapy ,Aged ,Neoplasm Staging ,Retrospective Studies ,Aged, 80 and over ,Pelvic exenteration ,business.industry ,Rectal Neoplasms ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Prognosis ,Total mesorectal excision ,Surgery ,Pelvic Exenteration ,Survival Rate ,Treatment Outcome ,030220 oncology & carcinogenesis ,Resection margin ,030211 gastroenterology & hepatology ,Female ,business - Abstract
Objective: The aim of the study was to analyze data from an international collaboration, and ascertain prognostic indicators that inform clinical decision-making and practices regarding the role of pelvic exenteration for locally advanced primary rectal cancer (LARC). Background: With improved national screening programs fewer patients present with LARC. Despite this, select cohorts of patients require pelvic exenteration. To date, the majority of outcome data are from single-center series. Methods: Anonymized data from 14 countries on patients who had pelvic exenteration for LARC between 2004 and 2014 were accumulated. The primary endpoint was overall survival. The impact of resection margin, nodal status, bone resection, and use of neoadjuvant therapy (before exenteration) on survival was evaluated using multivariable analysis. Results: Of 1291 patients, 778 (60.3%) were male with a median (range) age of 63 (18–90) years; 78.1% received neoadjuvant therapy. Bone resection en bloc was performed in 8.2% of patients (n¼ 106), and 22.6% (n¼ 292) had resection combined with flap reconstruction. Negative resection margin (R0 resection) was achieved in 79.9%. The 30-day postoperative mortality was 1.5%. The median overall survival following R0, R1, and R2 resection was 43, 21, and 10 months (P < 0.001) with a 3-year survival of 56.4%, 29.6%, and 8.1%, respectively (P < 0.001); 37.8% of patients experienced one or more major complication. Neoadjuvant therapy increased the risk of 30-day morbidity (P < 0.012). Multivariable analysis identified resection margin and nodal status as significant determinants of overall survival (other than advanced age). Conclusions: Attainment of negative resection margins (R0) is the key to survival. Neoadjuvant therapy may improve survival; however, it does so at the increased risk of postoperative morbidity.
- Published
- 2019